Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary IN
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-10 7:00 AM EST | Phio Pharmaceuticals Corp.
Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a major clinical milestone for its portfolio company, Inretio. The medical device innovator has successfully completed the first cohort of the First-in-Human (FIH) study for the PREVA™ Neuro-Thrombectomy System, moving
Technology, Biotechnology, Health
2026-02-10 7:00 AM EST | Therma Bright Inc.
Rapid Dose Therapeutics Launches QuickStrip(TM) Medical Cannabis for Patients in Brazil following ANVISA Approval of Sublingual and Buccal Formats for Medical Treatment
Burlington, Ontario--(Newsfile Corp. - February 10, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") , a Canadian biotechnology company focused on innovative drug delivery solutions, today announced the commercial launch of its Entourage Phytolab co-branded QuickStrip™ medical cannabis oral thin film in Brazil following regulatory approval for both manufacturing and distribution by Brazil's National Health Regulatory Agency (ANVISA). T
2026-02-10 7:00 AM EST | Rapid Dose Therapeutics Corp.
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board ("SAB") meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum® for antibody-drug conjugate ("ADC") applications. The discussion brought together complementary
Biotechnology, Pharmaceuticals, Health
2026-02-10 3:15 AM EST | Defence Therapeutics Inc.
TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super-Pharm, Israel's largest and most prominent pharmacy and health-retail chain, operating nationwide and serving millions of consumers annually.
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-10 3:00 AM EST | TempraMed Technologies Ltd.
Conexeu Sciences Appoints Sonia Thomas as Head of Strategy & Transformation to Accelerate Enterprise Growth and Execution Excellence
Reno, Nevada--(Newsfile Corp. - February 9, 2026) - Conexeu Sciences Inc. ("Conexeu" or the "Company") a biotechnology innovator redefining regenerative medicine through a next-generation extracellular matrix platform, is pleased to announce Sonia Thomas, MBA, as Head of Strategy & Transformation. In her role, Sonia will help define Conexeu's enterprise strategy, shape portfolio priorities, and long-term growth decisions, and lead cross-functional transformation initiatives
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-09 9:00 AM EST | Conexeu Sciences Inc.
Adia Nutrition Inc. Plans to Initiate Four to Five New Clinical Studies in 2026, Including Expansions in Autism and New Rheumatoid Arthritis Research
Winter Park, Florida--(Newsfile Corp. - February 9, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its subsidiary Adia Med, today announced an ambitious expansion of its clinical research pipeline, with plans to launch four to five additional studies throughout 2026. These new initiatives will build on the company's ongoing success in regenerative therapies using Adia Vita (umbilical cord blood-derived stem cells and exosomes).
Healthcare and Hospitals, Health
2026-02-09 8:31 AM EST | Adia Nutrition Inc.
Qscreen AI Announces Strategic U.S. Engagement to Drive Innovation in Public Safety and Institutional Health
Toronto, Ontario--(Newsfile Corp. - February 9, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), a pioneering leader in artificial intelligence enabled health and safety technology, is pleased to announce that it has entered into an independent contractor agreement with Global Frontier Advisors L.P. ("GFA"), effective January 30, 2026. GFA will receive a combination of equity-based along with performance-based compensation during the term of the agreement, subject to applicabl
2026-02-09 7:01 AM EST | QScreen AI Inc.
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed its first export of MDMA capsules to Australia in 2026 under the Authorised Prescriber Scheme. The export included 1,000 of Optimi's MDMA capsules in a standardised 60 mg dosage form, supplied for use in authorised cl
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-09 7:00 AM EST | Optimi Health Corp.
Cheelcare Announces $1.0 Million Unsecured Note Financing
Markham, Ontario--(Newsfile Corp. - February 9, 2026) - Cheelcare Inc. (TSXV: CHER) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced that it has entered into term sheets with strategic investors for a non-brokered unsecured promissory note (the "Notes") financing for gross proceeds of up to $1,000,000 (the "Offering"). The Offering is expected to include $750,000 from Pathfinder Asset Management Ltd. ("PAML") and $
2026-02-09 7:00 AM EST | Cheelcare Inc.
PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents". The international patent application covers innovative methods and formulations aimed at ad
Biotechnology, Pharmaceuticals, Health
2026-02-09 3:00 AM EST | PreveCeutical Medical Inc.
Apollo Biowellness, Inc., Announces Termination of Distribution Agreement with Revive Regenerative, Inc.
North Bergen, New Jersey--(Newsfile Corp. - February 6, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company), announces that the 'Exclusive Distribution Agreement' dated July 1, 2025, between Evolutionary Biologics (a wholly owned subsidiary of Apollo Biowellness) and Revive Regenerative, Inc. ("Revive") has been "terminated for cause" by Evolutionary Biologics, for reasons already disclosed to Revive Regenerative, Inc. and is no longer in effect.
Household / Consumer / Cosmetics, Health
2026-02-06 9:30 AM EST | Apollo Biowellness, Inc.
TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed initial sales of VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med to pharmacies operated by Maccabi Healthcare Services ("Maccabi") and has launched a national i
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-06 3:00 AM EST | TempraMed Technologies Ltd.
NuGen Medical Devices Inc. Provides Update on Health Canada License
Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is initiating a temporary halt on its devices in Canada due to the lapse of its license with Health Canada. The Company's Health Canada Licence became expired due to an untimely certificate renewal. This is not a suspension or cancellation related to regulatory compliance or enforcement action. The temporary status does not constitute a product safety
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-05 5:15 PM EST | NuGen Medical Devices Inc.
James Anderson Provides Update on Holdings of MyndTec Inc.
Detroit, Michigan--(Newsfile Corp. - February 5, 2026) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On February 4, 2026, the Issuer completed an additional tranche (the "Current Tranche") of a private placement of units ("Units") announced on January 30, 2025. 650,970 Unit
Technology, Healthcare and Hospitals, Health
2026-02-05 4:52 PM EST | James Anderson
Orange Auto Insurance, Inc., Subsidiary of HPN Holdings, Inc. Announces Reinsurance Partnership
Chicago, Illinois--(Newsfile Corp. - February 5, 2026) - HPN Holdings, Inc. (OTCID: KICK) ("HPN" or the "Company") today announced that its subsidiary Orange Auto Insurance, Inc ("Orange"), a technology-driven nonstandard automobile insurance holding company and its managing general agency (Orange Underwriters, LLC) have obtained the reinsurance capacity to begin operations. The reinsurance and reinsurer partnership will provide Orange with the capacity to write up to $25 million in pr
2026-02-05 10:04 AM EST | HPN Holdings, Inc.
MyndTec Inc. Completes Additional Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - February 4, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed an additional tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The additional tranche of the private placement, the eleventh of the Offering, consists of 650,970 Units of the Company (the "
Technology, Healthcare and Hospitals, Health
2026-02-04 6:00 PM EST | MyndTec Inc.
This World Cancer Day, St. Baldrick's Foundation Leads the Charge Against Childhood Cancer
Los Angeles, California--(Newsfile Corp. - February 4, 2026) - This World Cancer Day, the St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants in the U.S., is shining a light on the urgent need for continued investment in childhood cancer research, and on the powerful global community working together to accelerate cures and develop better, safer treatments for children facing cancer. Wor
2026-02-04 2:00 PM EST | St. Baldrick's Foundation
Adia Nutrition Inc. Announces Effectiveness of Form 10 Registration Statement - Now a Fully Reporting SEC Company and Advancing Toward Next Phase of Growth and NASDAQ Uplisting
Winter Park, Florida--(Newsfile Corp. - February 4, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions through its Adia Med division, today announced that its Form 10 registration statement became effective on February 3, 2026, as anticipated and in accordance with the U.S. Securities and Exchange Commission's (SEC) prior notification. The Form 10, originally filed on December 5, 2025, was not subject to furt
Healthcare and Hospitals, Health
2026-02-04 9:32 AM EST | Adia Nutrition Inc.
Bloom Burton & Co. Announces the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce the launch of the 2026 Bloom Burton Award and to open nomination submissions from the public at large on or before March 27, 2026. The finalists for the 2026 Bloom Burton Award will be announced at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place at the Metro Toronto Convention Centre from April 21-22, 2026.
Technology, Biotechnology, Investment Banking, Health
2026-02-04 8:25 AM EST | Bloom Burton & Co. Inc.